Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33404570

about

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.Future agents and treatment directions in multiple myeloma.Salvage therapy of multiple myeloma: the new generation drugs.Bendamustine in multiple myeloma.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.

P2860

Q30828090-4F44D349-5CFC-4D8E-8F73-B62EC67E8A2B Q33410756-26DF54D7-865B-4125-8D61-38B904041613 Q33411440-187E7BB4-3E5F-4FB9-9826-2661DC62F7E1 Q33411708-0D61D410-194B-43E2-92D7-21B0D75F0607 Q33418389-750171E2-EFCF-4BC7-8406-812DDFB75C5D Q33442039-DC4A0777-C7EB-46AE-8870-E7E10E0479E0 Q37313790-4EA53948-CEB1-4B67-999F-008252690B18 Q38095526-6FFB861E-3D94-45DB-A1E1-88172D0540CC Q38139989-FE0FAF84-7E4B-44DA-9D64-8AA617075975 Q38172300-946EE313-3DBD-4061-BA7C-E0C825B49B3A Q38223433-3D882811-69C8-4C16-A0A4-142B6DAB7148 Q38530583-F9D1A671-7975-42EE-ACF5-B53892079723 Q38548134-CF588827-2EEC-46B2-BFB5-2BF08CB24695 Q38642648-BB6CF5E4-27B6-4937-90E5-834B5102B91C Q40095723-79659A19-EC6F-4A80-979C-53184FA6C736 Q41044036-C7F538B1-2E5C-4195-A138-F3AB0C0B15BD Q41253617-41426367-D0FA-44A4-87A3-1A09E5A8FF27 Q45892519-682358B8-5D97-4D28-9530-F44908E9076E Q48204298-0FCEC29E-075F-4439-9EA1-D686AA43B110 Q52841629-634D8D42-2A37-4359-A11B-D2AFB106C4B1 Q52958098-570903C3-A682-4E65-8621-E9FA9C4FD7AD Q53504691-B78B0F37-DC3C-43F3-8EE0-7B641C5EA6A2

P2860

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33404570

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@ast

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@en

type

label

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@ast

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@en

prefLabel

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@ast

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@en

P1433

Q33404570-2CE2C5F5-2F26-4E8F-9E4F-42D3577FFA68

P1476

Q33404570-3920C36C-DAC8-495C-91E2-4FEF3E3CE346

P2093

Q33404570-037E4C1E-B5C1-4426-BC14-13C927F7F27C

Q33404570-0F8A3AB9-35BA-4DB1-B73D-054780F0F880

Q33404570-284B811C-73A4-4BFB-BC91-5AE2846B7143

Q33404570-39B2C335-8CAD-4B41-9E11-D3931D96534E

Q33404570-3BDADFCE-0E21-4EC2-B86B-A27FE8BFB3FB

Q33404570-3D8BB898-0887-43A7-BD33-B6F60470E52A

Q33404570-48FE3B4F-05F1-461E-A4C1-407C0687B48F

Q33404570-4DBD1C58-54A8-4899-9A79-E8F86DD8D6E4

Q33404570-51271BC9-C461-4EDF-8577-CDA458EB13EA

Q33404570-597CC72D-7171-4C3E-AE86-BBB43FC066A1

P2860

Q33404570-0134E295-0602-49B7-84D4-CE6DC37AF7D4

Q33404570-036C3879-E82F-498B-A426-CDE4164F5E62

Q33404570-05F17DFC-C80D-4A5E-9BFF-61E91B26D806

Q33404570-066CAF3B-7E64-4888-BF08-C2B9515DCD72

Q33404570-138959E3-E826-409E-A408-7B7A790B0D93

Q33404570-1C2D9EC8-133E-495E-967B-C35CBD10078E

Q33404570-1FD3907E-F404-4FAE-92BC-05BB9BBB2857

Q33404570-25875B99-0AB6-4A1B-A745-363E2B6D6766

Q33404570-29192A3C-33E9-4323-BD9C-27957F3DC2AA

Q33404570-4E7FB5CC-7D90-4AFF-928C-5B6C3A6601A4

P2888

Q33404570-EBE84CB7-77AC-4E16-AF70-884A8C7D9726

P304

Q33404570-7B18D9B4-6113-4DBD-A5B4-DF590A478A7F

P31

Q33404570-1B8C6E99-693D-4818-B233-6DDC3C4C5B1E

P356

Q33404570-C77F5721-60AC-4784-8F0F-D690E9D50E65

P433

Q33404570-09B41502-0304-43D3-A0F2-D242D97D7685

P478

Q33404570-1CBE7E40-9BF2-4AAB-86AF-0577C85DEC03

P577

Q33404570-FBC9F80B-2495-4A39-9823-5B3D6C05BB99

P698

Q33404570-3CF04AC7-43DC-4482-8F11-81638F5B470C

P356

S00432-012-1339-3

P1433

Journal of Cancer Research and Clinical Oncology

P1476

Combined bendamustine, prednis ...... r refractory multiple myeloma.

@en

P2093

Andreas Schwarzer

http://www.w3.org/2001/XMLSchema#string

Barbara Moll

http://www.w3.org/2001/XMLSchema#string

Cornelia Becker

http://www.w3.org/2001/XMLSchema#string

Dietger Niederwieser

http://www.w3.org/2001/XMLSchema#string

Franz Albert Hoffmann

http://www.w3.org/2001/XMLSchema#string

Gerald Hensel

http://www.w3.org/2001/XMLSchema#string

Haifa Al Ali

http://www.w3.org/2001/XMLSchema#string

Hans-Jürgen Hurtz

http://www.w3.org/2001/XMLSchema#string

Ina Wagner

http://www.w3.org/2001/XMLSchema#string

Kerstin Löschcke

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

International uniform response criteria for multiple myeloma.

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

P2888

s00432-012-1339-3

P304

499-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-012-1339-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

139

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23184429

http://www.w3.org/2001/XMLSchema#string